Pembrolizumab: all 1,753 studies that test it
Page 16 of 18. Open to participants first (418), then studies with results posted, then the rest; newest registration first within each.
- Pembrolizumab With Chemotherapy in Metastatic or Unresectable High Grade Gastroenteropancreatic or Lung Neuroendocrine CarcinomaWithdrawnNCT03901378Phase 2
- Pembrolizumab for Newly Diagnosed GlioblastomaActive, not recruitingNCT03899857Phase 2
- Lenvatinib Combined Pembrolizumab in Advanced Hepatobiliary TumorsCompletedNCT03895970Phase 2
- Gut Microbiome Modulation to Enable Efficacy of Checkpoint-based Immunotherapy in Pancreatic AdenocarcinomaWithdrawnNCT03891979Phase 4
- First-line Esophageal Carcinoma Study With Chemo vs. Chemo Plus Pembrolizumab (MK-3475-590/KEYNOTE-590)-China Extension StudyWithdrawnNCT03881111Phase 3
- Pembrolizumab And Tamoxifen Among Women With Advanced Hormone Receptor Positive Breast Cancer And Esr1 MutationStatus unknownNCT03879174Phase 2
- Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME TrialTerminatedNCT03878524Phase 1
- A Study to Evaluate Safety and Therapeutic Activity of RO6874281 in Combination with Pembrolizumab, in Participants with Advanced or Metastatic MelanomaCompletedNCT03875079Phase 1
- First-in-Human Study of EOS100850 (Inupadenant) in Patients with CancerCompletedNCT03873883Phase 1
- A Study of CXD101 in Combination With Pembrolizumab for Relapsed or Refractory Diffuse Large B-Cell LymphomaWithdrawnNCT03873025Phase 1/2
- Pembrolizumab In Combination With Debio 1143 In Pancreatic and Colorectal Advanced/Metastatic AdenocarcinomaCompletedNCT03871959Phase 1
- A Dose Escalation and Cohort Expansion Study of Subcutaneously-Administered Cytokine ALKS 4230 (Nemvaleukin Alfa) as a Single Agent and in Combination With Anti-PD-1 Antibody (Pembrolizumab) in Subjects With Select Advanced or Metastatic Solid Tumors (ARTISTRY-2)CompletedNCT03861793Phase 1/2
- Testing the Addition of Tazemetostat to the Immunotherapy Drug, Pembrolizumab (MK-3475), in Advanced Urothelial CarcinomaActive, not recruitingNCT03854474Phase 1/2
- A Study of XmAb®22841 Monotherapy & in Combination w/ Pembrolizumab in Subjects w/ Selected Advanced Solid TumorsCompletedNCT03849469Phase 1
- A Study to Evaluate Immunotherapy Combinations in Participants With Lung CancerCompletedNCT03846310Phase 1
- Paclitaxel Plus Pembrolizumab vs. Paclitaxel Weekly in ER+ Luminal B Metastatic Breast CancerWithdrawnNCT03841747Phase 2
- AO-176 in Multiple Solid Tumor MalignanciesCompletedNCT03834948Phase 1/2
- Pembrolizumab-Epacadostat Combination to Treat Muscle-invasive Bladder UrotheLIAl canceR: PECULIAR StudyWithdrawnNCT03832673Phase 2
- Study of Pembrolizumab Following Surgery in Patients With Microsatellite Instability High (MSI-H) Solid TumorsActive, not recruitingNCT03832569Early Phase 1
- Phase II Trial of Pembrolizumab in Recurrent or Metastatic HNSCCActive, not recruitingNCT03813836Phase 2
- Study of INBRX-105 and INBRX-105 With Pembrolizumab in Patients With Solid Tumors Including Head and Neck CancerTerminatedNCT03809624Phase 1
- A Study of ASP1951 in Subjects With Advanced Solid TumorsTerminatedNCT03799003Phase 1
- Testing the Timing of Pembrolizumab Alone or With Chemotherapy as First Line Treatment and Maintenance in Non-small Cell Lung CancerActive, not recruitingNCT03793179Phase 3
- Vaccination With Flt3L, Radiation, and Poly-ICLCCompletedNCT03789097Phase 1/2
- A Study of EDP1503 in Patients With Colorectal Cancer, Breast Cancer, and Checkpoint Inhibitor Relapsed TumorsCompletedNCT03775850Phase 1
- MRD-guided Treatment in NPM1mut AML PatientsTerminatedNCT03769532Phase 2
- Neoadjuvant PD-1 Blockade in Patients With Stage IIB/C MelanomaActive, not recruitingNCT03757689Phase 2
- Neoadjuvant Pembrolizumab Plus Androgen Axis Blockade Prior to Prostatectomy for High Risk Localized Prostate CancerStatus unknownNCT03753243Phase 2
- Pembrolizumab in Treating Participants With Recurrent Ovarian CancerActive, not recruitingNCT03732950Phase 2
- ICIs Neoadjuvant Therapy in Resectable Non-Small-Cell Lung CancerCompletedNCT03732664Phase 1
- Phase 2 Study of Pembrolizumab+Carboplatin in Breast Related Cancer Antigens-related Metastatic Breast Cancer (PEMBRACA)CompletedNCT03732391Phase 2
- CART-EGFRvIII + Pembrolizumab in GBMCompletedNCT03726515Phase 1
- Study of Pembrolizumab (MK-3475) Versus Placebo in Combination With Neoadjuvant Chemotherapy & Adjuvant Endocrine Therapy in the Treatment of Early-Stage Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative (ER+/HER2-) Breast Cancer (MK-3475-756/KEYNOTE-756)Active, not recruitingNCT03725059Phase 3
- Testing Pembrolizumab Versus Observation in Patients With Merkel Cell Carcinoma After Surgery, STAMP TrialActive, not recruitingNCT03712605Phase 3
- Efficacy and Safety of Pembrolizumab (MK-3475) in Combination With Bacillus Calmette-Guerin (BCG) in High-Risk Non-Muscle Invasive Bladder Cancer (HR NMIBC) (MK-3475-676/KEYNOTE-676)Active, not recruitingNCT03711032Phase 3
- Clinical Trial of Safety, Tolerability and Antitumor Activity of Genetically Engineered T Cells in Combination With Anti-Cancer Agents in Relapsed and Refractory Synovial Sarcoma Expressing New York Esophageal Antigen-1 (NY-ESO-1) and/or LAGE-1aWithdrawnNCT03697824Phase 2
- Grapiprant (ARY-007) and Pembrolizumab in Patients With Advanced or Metastatic Post-PD-1/L1 NSCLC AdenocarcinomaTerminatedNCT03696212Phase 1/2
- Afatinib and Pembrolizumab for Head and Neck Squamous Cell Carcinoma (ALPHA Study)CompletedNCT03695510Phase 2
- Window of Opportunity Pilot Study of Pembrolizumab in Obesity-driven Endometrial CancerTerminatedNCT03694834Early Phase 1
- Intratumoral Cavrotolimod Combined With Pembrolizumab or Cemiplimab in Patients With Merkel Cell Carcinoma, Cutaneous Squamous Cell Carcinoma, or Other Advanced Solid TumorsTerminatedNCT03684785Phase 1/2
- Immunotherapy +/- EGFR Inhibitor In Advanced/Metastatic cSCC: Tackling Primary And Secondary ResistanceStatus unknownNCT03666325Phase 2
- Pembrolizumab in Association With the IMA950/Poly-ICLC for Relapsing GlioblastomaCompletedNCT03665545Phase 1/2
- PRINCE (PSMA-lutetium Radionuclide Therapy and ImmuNotherapy in Prostate CancEr)CompletedNCT03658447Phase 1/2
- Chemotherapy With Pembrolizumab Continuation After Progression to PD-1/L1 InhibitorsStatus unknownNCT03656094Phase 2
- Effect of Pembrolizumab and Cisplatin on Metastatic, Locally Recurrent or Inoperable Triple-Negative Breast CancerWithdrawnNCT03644589Phase 2
- Live Biotherapeutic Product MRx0518 and Pembrolizumab Combination Study in Solid TumorsTerminatedNCT03637803Phase 1/2
- Second-line Study of PEGPH20 and Pembro for HA High Metastatic PDACStatus unknownNCT03634332Phase 2
- Study of Tisagenlecleucel in Combination With Pembrolizumab in r/r Diffuse Large B-cell Lymphoma PatientsCompletedNCT03630159Phase 1
- A Study of APG-115 in as a Monotherapy or Combination With Pembrolizumab in Patients With Metastatic Melanomas or Advanced Solid TumorsActive, not recruitingNCT03611868Phase 1/2
- Pembro + Blina Combination in Pediatric and Young Adult Patients With Relapsed/Refractory Acute Leukemia or LymphomaWithdrawnNCT03605589Phase 1
- Chemokine Modulation Therapy and Pembrolizumab in Treating Participants With Metastatic Triple-Negative Breast CancerCompletedNCT03599453Early Phase 1
- Study to Evaluate the Safety and Efficacy of a Combination of Favezelimab (MK-4280) and Pembrolizumab (MK-3475) in Participants With Hematologic Malignancies (MK-4280-003)TerminatedNCT03598608Phase 1/2
- Epacadostat and Pembrolizumab Before Surgery in Treating Participants With Stage II-III Esophageal or Gastroesophageal CancerWithdrawnNCT03592407Phase 2
- Abexinostat in Combination With Pembrolizumab in Patients With Advanced Solid Tumor MalignanciesCompletedNCT03590054Phase 1
- Study of Oraxol and Pembrolizumab in Subjects With Advanced Solid TumorsTerminatedNCT03588039Phase 1
- Pembrolizumab in Relapsed or Refractory Extranodal NK/T- Cell Lymphoma, Nasal Type and EBV-associated Diffuse Large B Cell LymphomasWithdrawnNCT03586024Phase 1/2
- Pembrolizumab After Lung SBRT for Medically Inoperable Early Stage Non-small Cell Lung CancerWithdrawnNCT03574220Early Phase 1
- A Study of ASP1948, Targeting an Immune Modulatory Receptor as a Single Agent and in Combination With a PD-l Inhibitor (Nivolumab or Pembrolizumab) in Subjects With Advanced Solid TumorsCompletedNCT03565445Phase 1
- Study of MK-4830 as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-4830-001)CompletedNCT03564691Phase 1
- Study of Sacituzumab Govitecan in Participants With Urothelial Cancer That Cannot Be Removed or Has SpreadActive, not recruitingNCT03547973Phase 2
- Peri-Operative Immune Checkpoint Inhibition and Cryoablation in Women With Triple-negative Breast CancerActive, not recruitingNCT03546686Phase 2
- SBRT +/- Pembrolizumab in Patients With Local-Regionally Recurrent or Second Primary Head and Neck CarcinomaActive, not recruitingNCT03546582Phase 2
- Pembrolizumab Plus Autologous Dendritic Cell Vaccine in Patients with PD-L1 Negative Advanced Mesothelioma Who Have Failed Prior TherapiesActive, not recruitingNCT03546426Phase 1
- CCL21-Gene Modified Dendritic Cell Vaccine and Pembrolizumab in Treating Patients With Stage IV Non-small Cell Lung CancerActive, not recruitingNCT03546361Phase 1
- Pembrolizumab for Nasopharyngeal Carcinoma Patients With Detectable Plasma Epstein-Barr Virus DNATerminatedNCT03544099Phase 2
- Study on MK-3475 Plus Chemotherapy Versus Chemotherapy Alone in Recurrent, Platinum-resistant Ovarian CancerStatus unknownNCT03539328Phase 2
- Analysis of the Modulation of the Tumor Microenvironment by MK-3475 (Pembrolizumab) Using a Systems Biology Approach (PEMSYS)Active, not recruitingNCT03534635Phase 2
- Pembrolizumab and Dasatinib, Imatinib Mesylate, or Nilotinib in Treating Patients With Chronic Myeloid Leukemia and Persistently Detectable Minimal Residual DiseaseActive, not recruitingNCT03516279Phase 2
- Study of Immunotherapy in Combination With Chemotherapy in HER2-negative Inflammatory Breast CancerActive, not recruitingNCT03515798Phase 2
- Pembrolizumab and Blinatumomab in Treating Participants With Recurrent or Refractory Acute Lymphoblastic LeukemiaActive, not recruitingNCT03512405Phase 1/2
- Pembrolizumab (MK-3475) and Bacillus Calmette-Guérin (BCG) as First-Line Treatment for High-Risk T1 Non-Muscle-Invasive Bladder Cancer (NMIBC) and High-Grade Non-Muscle-Invasive Upper Tract Urothelial Carcinoma (NMI-UTUC)]Active, not recruitingNCT03504163Phase 2
- Pembrolizumab and Paclitaxel in Hypermutated Breast CancerCompletedNCT03492918Phase 2
- BDB001-101: Clinical Study of BDB001 as a Mono-therapy or in Combination With PembrolizumabCompletedNCT03486301Phase 1
- Postoperative aRCH With Cisplatin Versus aRCH With Cisplatin and Pembrolizumab in Locally Advanced Head and Neck Squamous Cell CarcinomaCompletedNCT03480672Phase 2
- Safety and Efficacy Study of Tenalisib (RP6530) in Combination With Pembrolizumab in Relapsed or Refractory cHLTerminatedNCT03471351Phase 1
- Phase II Multicentric Study of Pembrolizumab in Classic or Endemic Kaposi's SarcomaStatus unknownNCT03469804Phase 2
- Pembrolizumab and Nab Paclitaxel in Patients With Metastatic Urothelial CarcinomaCompletedNCT03464734Phase 2
- Pembrolizumab and Sunitinib Malate in Treating Participants With Refractory Metastatic or Unresectable Thymic CancerActive, not recruitingNCT03463460Phase 2
- CPI-006 Alone and in Combination With Ciforadenant and With Pembrolizumab for Patients With Advanced CancersCompletedNCT03454451Phase 1
- ECT-Pembrolizumab in Patients With Unresectable Melanoma With Superficial or Superficial and Visceral MetastasesWithdrawnNCT03448666Phase 2
- Pembrolizumab in First Line Treatment of Advanced NSCLC Patients With PD-L1 Low Tumors.Status unknownNCT03447678Phase 2
- Pembrolizumab in Combination With Decitabine and Hypofractionated Index Lesion Radiation in Pediatrics and Young AdultsCompletedNCT03445858Early Phase 1
- Pembrolizumab With Intratumoral Injection of Clostridium Novyi-NTActive, not recruitingNCT03435952Phase 1
- Epacadostat and Pembrolizumab in Treating Participants With Advanced Pancreatic CancerWithdrawnNCT03432676Phase 2
- Pembrolizumab in Hepatocellular CarcinomaActive, not recruitingNCT03419481Phase 2
- GRN-1201 With Pembrolizumab in Subjects With Metastatic PD-L1+ NSCLCTerminatedNCT03417882Phase 2
- Pembrolizumab With Chemotherapy in Front Line Advanced Ovarian, Primary Peritoneal and Fallopian Tube CancerStatus unknownNCT03410784Phase 2
- Apatinib With Pembrolizumab in Previously Treated Advanced MalignanciesTerminatedNCT03407976Phase 1
- ALCMI-005: Pembrolizumab and Epacadostat in Treating Patients With Extensive Stage Small Cell Lung CancerWithdrawnNCT03402880Phase 2
- Study of LYC-55716 With Pembrolizumab in Adult Subjects With Non-Small Cell Lung CancerStatus unknownNCT03396497Phase 1
- Pembrolizumab in Treating Patients With Metastatic or Unresectable Gastroesophageal AdenocarcinomaCompletedNCT03395847Early Phase 1
- Study of Pembrolizumab Plus Fulvestrant in Hormone Receptor Positive, HER-2 Negative Advanced/Metastatic Breast Cancer PatientsActive, not recruitingNCT03393845Phase 2
- A Trial Assessing the Effect of Pembrolizumab Combined with Radiotherapy in Patients with Relapsed, Refractory, Specified Stages of Cutaneous T-cell Lymphoma (CTCL) Mycosis Fungoides (MF)/Sezary Syndrome (SS)Active, not recruitingNCT03385226Phase 2
- Propranolol Hydrochloride and Pembrolizumab in Treating Patients With Stage IIIC-IV Melanoma That Cannot Be Removed by SurgerySuspendedNCT03384836Phase 1/2
- Chemoradiation vs Immunotherapy and Radiation for Head and Neck CancerActive, not recruitingNCT03383094Phase 2
- A Personal Cancer Vaccine (NEO-PV-01) With Pembrolizumab and Chemotherapy for Patients With Lung CancerCompletedNCT03380871Phase 1
- Pembrolizumab (MK-3475) as Maintainance in Treated Patients With Unresectable Stage III NSCLCStatus unknownNCT03379441Phase 2
- Pegzilarginase and Pembrolizumab for Extensive Disease Small Cell Lung CancerCompletedNCT03371979Phase 1/2
- PVX-410 Vaccine Plus Pembrolizumab in HLA-A2+ Metastatic Triple Negative Breast CancerActive, not recruitingNCT03362060Phase 1
- Personalized Neoantigen Cancer Vaccine + Pembrolizumab After Rituximab for Follicular LymphomaActive, not recruitingNCT03361852Phase 1